Full-Time

Vice President Sales & Marketing

Posted on 7/3/2025

BridgeBio

BridgeBio

501-1,000 employees

Develops therapies for genetic diseases

Compensation Overview

$340k - $390k/yr

+ Bonus + Equity

Palo Alto, CA, USA + 1 more

More locations: San Francisco, CA, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Forecasting
Branding/Brand Strategy
Data Analysis
Requirements
  • Experience: Minimum 15 years of pharmaceutical/biotech industry experience with at least 5 years in a senior sales and marketing leadership role in rare diseases, orphan drugs, or ultra-rare indications.
  • Launch Expertise: Proven track record leading U.S. commercial launches for rare disease or specialty care therapies.
  • Strategic & Operational Balance: Ability to define vision and strategy while also rolling up sleeves to drive tactical execution.
  • Stakeholder Management: Skilled at influencing and aligning internal stakeholders across multiple functions.
  • Advocacy Engagement: Deep experience collaborating with rare disease advocacy organizations and patient communities.
  • Market Understanding: Strong knowledge of U.S. market access, distribution models, and stakeholder dynamics in rare disease environments.
  • Education: Bachelor’s degree required; MBA or advanced degree preferred.
  • Travel: Ability to travel is required.
Responsibilities
  • Launch Strategy & Brand Building: Develop and execute U.S. commercial launch strategies tailored to rare disease markets, including brand positioning, messaging, and multichannel promotional strategies.
  • Develop and lead the U.S. sales and marketing strategy from commercialization and growth.
  • Drive all aspects of brand strategy, positioning, messaging, and multichannel marketing plans.
  • Lead pre-launch and launch activities including KOL engagement, disease awareness campaigns, and patient advocacy partnerships.
  • Conduct in-depth market analysis including competitive landscape, customer insights, and forecasting.
  • Translate scientific and clinical data into impactful marketing messages for physicians, patients, and caregivers.
  • Collaborate with patient advocacy groups to ensure the voice of the patient is integrated into marketing strategies.
  • Create tailored solutions for rare patient populations, ensuring accessibility, awareness, and education.
  • Establish differentiated disease awareness and educational campaigns to support early diagnosis and treatment access.
  • Collaborate with cross-functional launch teams, including Medical Affairs, Market Access, Regulatory, and Clinical Development, to ensure readiness and alignment.
  • Cross-Functional & External Leadership: Partner closely with Patient Advocacy, Access & Reimbursement, and Field Medical to ensure cohesive execution of commercial strategy.
  • Build and nurture strong relationships with external stakeholders, including key opinion leaders, advocacy groups, patient organizations, and specialty providers.
  • Serve as the primary point of contact for marketing agencies, consultants, and vendors supporting the rare disease program.
  • Team Leadership & Execution: Hire, lead, and mentor a growing marketing team capable of executing high-impact campaigns in complex and underserved markets.
  • Foster a culture of innovation, accountability, and patient-centricity throughout the commercial organization.
  • Ensure all marketing tactics are compliant with regulatory and legal standards, including collaboration with internal Compliance teams.
  • Program & Budget Oversight: Oversee the development and management of the rare disease program marketing budget.
  • Track and evaluate key performance indicators to optimize campaign effectiveness and ROI.
Desired Qualifications
  • MBA or advanced degree

BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Attruby generated $180.6 million U.S. net product revenue in Q1 2026.
  • BridgeBio filed an NDA for encaleret after positive Phase 3 CALIBRATE results.
  • BBP-418 met interim Phase 3 FORTIFY endpoints in LGMD2I/R9.

What critics are saying

  • Attruby remains the only meaningful commercial product today.
  • BridgeBio reported a $724.9 million net loss in 2025.
  • Encaleret and BBP-418 both face binary regulatory and late-stage execution risk.

What makes BridgeBio unique

  • BridgeBio runs a decentralized hub-and-spoke model for rare genetic disease programs.
  • Attruby is approved across the U.S., EU, Japan, Switzerland, and the U.K.
  • The company pairs central clinical infrastructure with autonomous disease-focused subsidiaries.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BridgeBio who can refer or advise you

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 15th, 2026
BridgeBio Pharma shares drop 8% in a month despite 110% yearly gain and analyst target of $100

BridgeBio Pharma has fallen 8% over the past month and 7% over three months, despite posting a 110.52% one-year total shareholder return and approximately 4x returns over three years. The company closed at $69.41, with analysts from Vestra pointing to a fair value of $100.05, suggesting it's 30.6% undervalued. The valuation gap depends on BridgeBio's late-stage pipeline and its transition from research and development to commercial operations. However, the company continues to carry annual net losses of approximately $724.9 million, keeping financing and execution risks prominent. A separate DCF model estimates future cash flow value at $302.08, though this relies heavily on long-term assumptions around successful regulatory approvals and commercial uptake across its rare disease portfolio.

Yahoo Finance
Mar 7th, 2026
BridgeBio's BBP-418 hits Phase 3 endpoints in LGMD2I/R9, but $673M loss tests diversification thesis

BridgeBio Pharma announced positive interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9, meeting efficacy endpoints. The company will present expanded results at the 2026 MDA Clinical and Scientific Conference alongside additional research. The successful readout represents a significant step for BBP-418 as a potential therapy for the rare genetic muscle disorder and could help diversify BridgeBio's revenue beyond its single approved drug, Attruby. However, the company remains unprofitable, reporting US$502 million in revenue against a US$725 million net loss in 2025. Analysts project BridgeBio could reach US$1.7 billion in revenue by 2028, with a fair value estimate of US$100.05 per share. The key risk remains high cash burn and potential dilution if expenses continue outpacing revenue growth.

Yahoo Finance
Mar 6th, 2026
Truist raises BridgeBio price target to $95 as Attruby sales hit $146M in Q4

BridgeBio Pharma has received upgraded price targets from analysts following strong fourth-quarter results. Truist raised its target to $95 from $86, maintaining a Buy rating, whilst Morgan Stanley increased its target to $98 from $96 with an Overweight rating. The company reported fourth-quarter revenue of $154.18 million, exceeding the $149.07 million consensus estimate. Pre-announced sales of its drug Attruby reached $146 million, a 35% increase from the third quarter, driven by accelerating new patient additions. CEO Neil Kumar highlighted the company's delivery of three successful Phase 3 trial readouts within three months. BridgeBio develops medicines for patients with genetic diseases and anticipates having six approved products as it completes its first decade.

Yahoo Finance
Jan 20th, 2026
Analysts raise BridgeBio price target to $86 after $362M Attruby revenue in 2025

BridgeBio Pharma has received positive analyst coverage following strong 2025 results. Truist raised its price target to $86 from $80 whilst maintaining a Buy rating, noting unchanged fundamental views from 2025. At the J.P. Morgan Healthcare Conference on 12 January, BridgeBio announced preliminary unaudited revenues of $146 million for the fourth quarter of 2025, bringing full-year product revenue to $362.4 million. The company reported over 6,000 unique prescriptions for Attruby, demonstrating rapid market adoption as a first-choice treatment for newly diagnosed ATTR-CM patients. BridgeBio develops therapies for genetic diseases and cancers, including its oncology-focused spin-off, BridgeBio Oncology Therapeutics, which advances precision cancer treatments targeting oncogenes like RAS and PI3K.

Stock Titan
Jan 16th, 2026
BridgeBio prices $550M convertible notes offering to prefund 2027 debt repayment

BridgeBio has priced an offering of $550 million in convertible senior notes due 2033. The biotech company plans to use the proceeds to prefund the repayment of its existing convertible senior notes due 2027. The refinancing move allows BridgeBio to extend its debt maturity profile by six years whilst managing its capital structure ahead of the 2027 notes coming due.

INACTIVE